Name: Radiopharmaceutical Manufacturing Market Size 2035
Creator: Roots Analysis
Published: 2026-09-18T00:00:01+05:30
License: https://www.rootsanalysis.com/terms.html
Keywords: Radiopharmaceutical Manufacturing Market, Radiopharmaceutical Manufacturing Market Growth, Radiopharmaceutical Manufacturing Market Trends, Radiopharmaceutical Manufacturing Market Size, Radiopharmaceutical Manufacturing Market Share, Radiopharmaceutical Manufacturing Market Analysis, Radiopharmaceutical Manufacturing Market Forecast, Radiopharmaceutical Manufacturing Market Report, Global Radiopharmaceutical Manufacturing Market, Radiopharmaceutical Manufacturing Industry

Market Outlook

The global radiopharmaceutical manufacturing market, valued at USD 5.86 billion in 2025, is projected to reach USD 6.61 billion in 2026 and USD 13.79 billion by 2035, representing a CAGR of 8.5% during the forecast period from 2026 to 2035.

Global Radiopharmaceutical Manufacturing Market Growth 2025 to 2035

See What's in the Full Report – Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

In terms of application area, diagnostic radiopharmaceuticals hold the highest share (around 70%) of the current market.
With respect to diagnostic radiopharmaceuticals, SPECT radiopharmaceuticals dominate the current market.
Based on the therapeutic radiopharmaceuticals, gamma emitters capture the largest share (nearly 65%) of the current market; this trend is unlikely to change in the future.
Amongst the type of radioisotope, Technetium-99m captures most of the current market.
With respect to the purpose of manufacturing, in-house manufacturers dominate the current market.
Based on the source of manufacturing, nuclear reactors capture the largest share of the current market; this trend is unlikely to change in the future.
With respect to the scale of operation, commercial scale dominates (nearly 85%) the current market.
In terms of the therapeutic area, oncological disorders hold the highest share of the current market.
In terms of geographical regions, North America currently holds the highest market share (more than 45%).

Key Market Statistics

Market Size in 2026: $ 6.61 Billion
Estimated Market Size in 2035: $ 13.79 Billion
CAGR (2026-2035): 8.5%
North America: Largest market in 2026
Asia-Pacific: Fastest growing region

Market Introduction

Radiopharmaceuticals are specialized drugs that use radioactive isotopes to diagnose and treat various medical conditions, most notably cancer. Over the past few years, radiopharmaceutical developers have extensively used various diagnostic and therapeutic procedures owing to their very short half-life, specificity to targets, and high affinity.

Regulatory agencies have approved over 65 radiopharmaceuticals across the world for the diagnosis and treatment of a myriad of chronic diseases, including infectious diseases, immunological disorders, gastroenteric diseases, cardiovascular disorders, chronic kidney diseases, oncological disorders, neurological disorders, and even certain psychiatric conditions. According to an article published by the World Nuclear Association, more than 10,000 hospitals worldwide claim to use radioisotopes for various diagnostic and therapeutic procedures. Further, it is worth highlighting that healthcare professionals conduct around 40 million diagnostic procedures annually that utilize only one radioisotope, Technetium-99m. Typically, healthcare professionals perform diagnostic tests using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). The introduction of the concept of theranostics, which involves the usage of a single active ingredient for both diagnostic and therapeutic purposes, has opened a new era in patient- centric treatment approach.

The development and production of radiopharmaceuticals are fraught with several challenges, including shortage of production capacity, complex manufacturing processes, lack of skilled labor and stringent guidelines mandated by regulatory agencies. This has prompted drug developers to outsource certain key operations (specifically the complex manufacturing processes) to contract service providers, which further help reduce the cost and expedite the launch of their radioactive drug products in the market. Owing to the increasing research activity and ongoing technological advancements in the field of radiopharmaceuticals, along with the growing burden of chronic diseases, the radiopharmaceutical manufacturing market is likely to witness exponential market growth during the forecast period.

Scope, Methodology and Industry Experts Interviews

The market for radiopharmaceutical manufacturing has a transformative future and is likely to grow at a notable CAGR in the future.

Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina) stated, "The demand for radiopharmaceuticals is going to rise in the near future. This can be primarily attributed to the several newly discovered applications of such products in therapy. In the next few years, we are expecting new therapeutic procedures involving nuclear medicine to hit the market, especially for tumors that are currently considered incurable, such as prostate cancer. Further, there has been a lot of progress in terms of the development of new tracers for both therapy and diagnostic purposes, for use across several disease indications. Therefore, it is safe to expect a substantial growth in the need for nuclear medicines in the coming years."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

Head of Business Unit Pharmaceuticals, Mid-sized Company, Austria
Senior Vice President of Business Development, Mid-sized Company, US
Former Vice President, Quality / R&D, Small Company, US
Professor of Nuclear Medicine, Large Company, Greece
Retired Professor of Medical Imaging / Nuclear Medicine Physician, Very Large Company, Netherlands
Associate Director and Director, Very Large Company, US
Anonymous, Large Company, Germany

In addition, the market report includes transcripts of the following other third-party discussions:

Chief Executive Officer, Small Company, Canada
Chief Executive Officer, Small Company, Australia
Chief Executive Officer, Mid-sized Company, US
Chief Executive Officer, Large Company, Germany
Chair, Department of Radiology, Large Organization, US
President, Mid-sized Company, US
Vice President, Clinical Development, Large Organization, US
Director and Medical Director, Large Organization, US
Radiation Oncologist and Co-director, Very Large Organization, US
Doctor of Medicine, Very Large Organization, US

Pay Only for What You Need – The Best Way to Optimize

Market Segmentation

Based on our research, we have segmented the radiopharmaceutical manufacturing market into application area, type of diagnostic radiopharmaceutical, type of therapeutic radiopharmaceutical, type of radioisotope, purpose of manufacturing, source of manufacturing, scale of operation, therapeutic area and geographical regions.

Application Area: Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals
Type of Diagnostic Radiopharmaceutical: SPECT Radiopharmaceuticals and PET Radiopharmaceuticals
Type of Therapeutic Radiopharmaceutical: Gamma Emitters, Beta Emitters, and Others
Type of Radioisotope: Technetium-99m, Lutetium-177, Fluorine-18, and Others
Purpose of Manufacturing: In-House Manufacturing and Contract Manufacturing
Source of Manufacturing: Nuclear Reactors, Accelerators / Cyclotrons, and Others
Scale of Operation: Preclinical Scale, Clinical Scale, and Commercial Scale
Therapeutic Area: Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Hormonal Disorders, Gastrointestinal Disorders, and Other Disorders
Geographical Regions: North America (US and Canada), Europe (Germany, France, Spain, Italy, UK, and Rest of Europe), Asia-Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Middle East and North Africa (Israel, South Africa, and Rest of Middle East and North Africa)

Your Business is Unique – Why Shouldn't Your Report Be?

Radiopharmaceutical Manufacturing Market Key Insights

What are the Key Drivers for Radiopharmaceutical Manufacturing Market Growth?

Rising Prevalence of Chronic Disorders: The rising demand for advanced therapeutic modalities for the treatment of various chronic diseases drives the growth of the radiopharmaceutical manufacturing market. It is worth highlighting that researchers are conducting several clinical trials to investigate radiotherapeutics for the treatment of a wide range of diseases across different geographies. This demonstrates the extensive development efforts that stakeholders are undertaking in this domain.
Increasing Interest Towards Targeted Radiation Therapy: Drug developers have extensively focused on developing targeted radionuclide-based drug therapies in order to overcome the limitations of conventional treatment options. Traditional approaches such as external-beam radiotherapy and systemic chemotherapy often lack tumor specificity, resulting in substantial damage to healthy tissues and dose-limiting toxicities. In contrast, targeted radio-nuclide therapies deliver ionizing radiation selectively to malignant cells via tumor-specific ligands (biologics (peptides, antibodies), or small molecules), enabling higher therapeutic indices while sparing surrounding normal tissue.

What are the Main Challenges for Market Growth?

Evolving Regulatory Landscape: Stringent regulatory guidelines govern the development and approval of new radiopharmaceuticals. Unlike conventional pharmaceuticals, authorities require dual regulatory approval involving radiation exposure and effects, toxicological studies, pharmacokinetic modelling, and imaging studies.
Short Half-life of Radiopharmaceuticals: Failure to use a radiopharmaceutical within its specified shelf life or before sufficient radioactive decay occurs may reduce its activity below the required level for diagnosis or treatment.

What are the Key Radiopharmaceutical Manufacturing Market Trends?

Partnerships and Collaborations: Several radiopharmaceutical manufacturing companies have recently pursued partnerships to strengthen their market position. Supply agreements emerged as the most prominent partnership model, closely followed by acquisitions. Companies undertake such collaborations to rapidly expand clinical and commercial capabilities, lower development risks, and bypass heavy internal investment. In May 2026, Ratio Therapeutics expanded its manufacturing agreement with PharmaLogic with the aim of supporting clinical development of [Ac-225]RTX-2358.
Scale-up by Contract Manufacturing Organizations (CMOs): Surging demand for diagnostic and therapeutic radiopharmaceuticals (particularly radioligand therapies using isotopes such as Lutetium-177 and Actinium-225) accelerates the need for radiopharmaceutical contract manufacturers. In April 2026, Nucleus RadioPharma secured USD 50 million financing from OrbiMed to expand manufacturing capacity at its Philadelphia facility with the aim of addressing critical infrastructure needs in precision oncology.

Recent Developments in Radiopharmaceutical Manufacturing Market

In May 2026, BAMF Health and Sentara Health entered into a joint venture agreement to create Virginia's first comprehensive vertically integrated Theranostics program.
In April 2026, Cardinal Health announced the expansion of its Actinium-225 (Ac-225) production capabilities at the company's Center for Theranostics Advancement (CTA) in Indianapolis, Indiana.
In February 2026, DuChemBio entered into a technology development agreement with Neurophet aimed at developing a next-generation degenerative brain disease diagnosis platform that combines radiopharmaceuticals and artificial intelligence.

Which Application Area Accounts for the Largest Share in the Radiopharmaceutical Manufacturing Market?

In 2026, diagnostic radiopharmaceuticals hold around 70% of the overall market share, driven by the growing usage of PET and SPECT imaging in early-stage oncology and cardiology, where Technetium-99m remains the primary isotope for diagnostic imaging. In addition, the expansion of diagnostic imaging centers across developing regions and the increasing clinical reliance on molecular imaging provide a predictable, long-term revenue stream with high barriers to entry.
The therapeutic radiopharmaceuticals segment is likely to grow at a higher CAGR (10.9%) during the forecast period. The theranostics revolution and the success of targeted ligands, such as Lutetium-177 and Actinium-225, which are transforming end-stage cancer treatment, propel this lucrative growth.

Global Radiopharmaceutical Manufacturing Market Size by Application Area, 2026

Which Type of Therapeutic Radiopharmaceutical Accounts for the Largest Share in the Radiopharmaceutical Manufacturing Market?

In 2026, gamma emitters hold around 65% of the overall market share due to the widespread adoption of Lutetium-177 and Yttrium-90, which are the primary isotopes for treating high-prevalence conditions, such as neuroendocrine tumors and prostate cancer. Companies that control high-purity Lutetium supplies and possess integrated cold-chain logistics hold a major advantage in this segment, serving as the high-yield utility players of oncology precision medicine.
In addition, we anticipate the beta emitters segment to witness a higher CAGR (10.7%) during the forecast period. This is due to the widespread adoption of Lutetium-177 and Yttrium-90, which are the primary isotopes for treating high-prevalence conditions, such as neuroendocrine tumors and prostate cancer.

Which Type of Radioisotope Accounts for the Largest Share in the Radiopharmaceutical Manufacturing Market?

According to the radiopharmaceutical manufacturing market forecast, the Technetium-99m segment accounts for around 50% of the overall market revenue. This is due to its favorable physical properties, broad diagnostic applications, and well-established production and distribution infrastructure.
The Fluorine-18 segment is likely to grow at a higher CAGR (10.2%) during the forecast period.

Which Therapeutic Area Accounts for the Largest Share in the Radiopharmaceutical Manufacturing Market?

According to the radiopharmaceutical manufacturing market forecast, the oncological disorders segment accounts for around 40% of the overall market revenue currently. This highest share is driven by the global prevalence of prostate, lung, and breast cancers, where radiopharmaceuticals have become the standard for both precise PET/SPECT staging and targeted treatments using isotopes, such as Lutetium-177. As cancer cases continue to increase, companies with proprietary ligands and large-scale oncology manufacturing hubs are capturing massive valuation premiums by addressing a non-discretionary and expanding patient pool.
In the future, the neurological disorders segment is likely to grow at a faster pace (9.5%), owing to the growing shift toward molecular imaging for early Alzheimer's and Parkinson's detection, especially with the recent approvals of amyloid-targeting PET tracers.

Regional Analysis: Which Regions are Showing the Fastest Growth in Radiopharmaceutical Manufacturing Industry?

North America Dominates the Market

North America is likely to capture the majority (more than 45%) of the radiopharmaceutical manufacturing market share in 2026, driven by an advanced healthcare ecosystem, high R&D investment, and favorable reimbursement policies that accelerate the adoption of high-priced targeted therapies. In addition, the presence of leading players and a mature regulatory framework (FDA) provide a clear path for commercializing high-margin innovations, such as theranostics ligands.

Asia-Pacific will grow at a relatively faster pace till 2035. Massive infrastructure investments in China and India, including a surge in regional cyclotron facilities and the localization of isotope production to mitigate import reliance, fuel this rapid growth. The convergence of an aging population and government-led nuclear medicine programs create an unprecedented demand for diagnostic and therapeutic capacity in previously underserved urban centers.

Global Radiopharmaceutical Manufacturing Market Share by Geographical Regions, 2026

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Scope of Radiopharmaceutical Manufacturing Market Report

Key Report Attribute	Details
Historical Trend	Since 2023
Forecast Period	Till 2035
Market Size 2026	$ 6.61 Billion
Market Size 2035	$ 13.79 Billion
CAGR (Till 2035)	8.5%
Players	Examples of players covered in the report include BAMF Health, Cardinal Health, DuChemBio, Eckert & Ziegler, Evergreen Theragnostics, Isotopia Molecular Imaging, PharmaLogic, Primo Biotechnology, RadioMedix, SpectronRx (A complete list of players captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

Report Authorship

Author(s): This report was authored by Simriti Gupta, part of Roots Analysis healthcare and pharma research practice, covering technology trends, competitive landscape, and adoption across pharmaceutical and biotechnology companies. All findings are based on proprietary databases, executive interviews, and regulatory analysis, and were subject to internal peer review prior to publication.

Independence and Non-Affiliation

Roots Analysis is an independent secondary and primary market research publisher. This report is not affiliated with, endorsed by, or produced on behalf of any company named or profiled within it, including all key players, and industry expert interviewees referenced above.

Roots Analysis' findings draw on a combination of secondary research and primary interviews with industry experts, of the kind referenced above, to validate market sizing, segment shares, and forecast assumptions independently of any single company's disclosures.

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

1.6. Chapter Outlines

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape

5.2. Executive Summary: Market Trends

5.3. Executive Summary: Market Forecast and Opportunity Analysis

+ 6. INTRODUCTION

6.1. Chapter Overview

6.2. Introduction to Nuclear Medicines and Radiopharmaceuticals

6.3. Historical Evolution of Radiopharmaceuticals

6.4. Applications of Radiopharmaceuticals

6.4.1. Nuclear Imaging / Diagnosis

6.4.2. Therapeutic Use

6.5. Production of Radiopharmaceuticals

6.6. Regulatory Framework for Radiopharmaceuticals

6.7. Need for Outsourcing Radiopharmaceuticals Manufacturing

6.8. Selecting a CMO Partner for Radiopharmaceuticals Manufacturing

6.9. Current Scenario and Future Prospects Related to Radiopharmaceuticals

6.10. Conclusion

+ 7. MARKET LANDSCAPE (INDUSTRY PLAYERS)

7.1. Chapter Overview

7.2. Radiopharmaceuticals Manufacturers (Industry Players): Overall Market Landscape

7.2.1. Analysis by Year of Establishment

7.2.2. Analysis by Company Size

7.2.3. Analysis by Location of Headquarters

7.2.4. Analysis by Company Size and Location of Headquarters

7.2.5. Analysis by Type of Company

7.2.6. Analysis by Location of Manufacturing Facilities

7.2.7. Analysis by Application Area

7.2.8. Analysis by Type of Diagnostic Radiopharmaceuticals Manufactured

7.2.9. Analysis by Type of PET Radiopharmaceuticals Manufactured

7.2.10. Analysis by Type of SPECT Radiopharmaceuticals Manufactured

7.2.11. Analysis by Type of Therapeutic Radiopharmaceuticals Manufactured

7.2.12. Analysis by Type of Alpha Emitters Manufactured

7.2.13. Analysis by Type of Beta Emitters Manufactured

7.2.14. Analysis by Type of Service Offered

7.2.15. Analysis by Scale of Operation

7.2.16. Analysis by Therapeutic Area

+ 8. MARKET LANDSCAPE (NON-INDUSTRY PLAYERS)

8.1. Chapter Overview

8.2. Radiopharmaceuticals Manufacturers (Non-Industry Players): Overall Market Landscape

8.2.1. Analysis by Location of Headquarters

8.2.2. Analysis by Type of Organization

8.2.3. Analysis by Application Area

8.2.4. Analysis by Type of Diagnostic Radiopharmaceuticals Manufactured

8.2.5. Analysis by Type of PET Radiopharmaceuticals Manufactured

8.2.6 Analysis by Type of SPECT Radiopharmaceuticals Manufactured

8.2.7. Analysis by Type of Therapeutic Radiopharmaceuticals Manufactured

8.2.8 Analysis by Type of Beta Emitters Manufactured

8.2.9 Analysis by Purpose of Manufacturing

8.2.10. Analysis by Therapeutic Area

+ 9. COMPANY COMPETITIVENSS ANALYSIS

9.1. Chapter Overview

9.2. Assumptions / Key Parameters

9.3. Methodology

9.4. Overview of Peer Groups

9.4.1. Peer Group I: Radiopharmaceuticals Manufacturers based in North America

9.4.2. Peer Group II: Radiopharmaceuticals Manufacturers based in Europe

9.4.3. Peer Group III: Radiopharmaceuticals Manufacturers based in Asia-Pacific

9.5. Company Competitiveness Analysis

9.5.1. Company Competitiveness Analysis: Radiopharmaceuticals Manufacturers based in North America

9.5.2. Company Competitiveness Analysis: Radiopharmaceuticals Manufacturers based in Europe

9.5.3. Company Competitiveness Analysis: Radiopharmaceuticals Manufacturers based in Asia-Pacific

+ 10. COMPANY PROFILES

10.1. Chapter Overview

10.2. BAMF Health

10.2.1. Company Overview

10.2.2. Service Portfolio

10.3. Cardinal Health

10.4. DuChemBio

10.5. Eckert & Ziegler

10.6. Evergreen Theragnostics

10.7. Isotopia Molecular Imaging

10.8. PharmaLogic

10.9 Primo Biotechnology

10.10. RadioMedix

10.11. Spectron Rx

* similar details are presented for other below mentioned players based on information in the public domain

+ 11. PARTNERSHIPS AND COLLABORATIONS

11.1. Chapter Overview

11.2. Partnership Models

11.3. Partnerships and Collaborations

11.3.1. Analysis by Quarterly Trend of Partnerships

11.3.2. Analysis by Type of Partnership

11.3.3. Analysis by Year and Type of Partnership

11.3.4. Analysis by Application Area

11.3.5. Analysis by Type of Radioisotope Involved

11.3.6. Analysis by Type of Partner

11.3.7. Most Active Players: Analysis by Number of Partnerships

11.3.8. Analysis by Geography

11.3.8.1. Local and International Deals

11.3.8.2. Intercontinental and Intracontinental Deals

+ 12. PRODUCTION AND SUPPLY CHAIN OF MOLYBDENUM-99 (TECHNETIUM-99M)

12.1. Chapter Overview

12.2. Production and Use of Mo-99

12.3. Supply Chain of Mo-99

12.3.1. Target Suppliers

12.3.2. Irradiation of Mo-99

12.3.3. Mo-99 Suppliers

12.3.4. Technetium Generator Suppliers

12.3.5. Tc-99 Suppliers

12.4. Supply Interruptions

12.5. Future Prospects

+ 13. GAP ASSESSMENT FRAMEWORK

13.1. Chapter Overview

13.2. Radiopharmaceutical Manufacturing Market: Gap Assessment Framework

13.2.1. Methodology

13.2.2. Key Parameters

13.2.2.1. Gap Assessment: Economic Infrastructure

13.2.2.2. Gap Assessment: Compliance Assurance

13.2.2.3. Gap Assessment: Streamlined Production

13.2.3. Strategic Roadmap to Address Market Gap

13.3. Regional Gap Assessment

13.3.1. Methodology

13.3.2. Regional Gap Assessment of Manufacturing Facilities in America

13.3.3. Regional Gap Assessment of Manufacturing Facilities in Europe

13.3.4. Regional Gap Assessment of Manufacturing Facilities in Asia-Pacific and Middle East

13.4. Concluding Remarks

+ 14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

14.1. Chapter Overview

14.2. Market Drivers

14.3. Market Restraints

14.4. Market Opportunities

14.5. Market Challenges

14.6. Conclusion

+ 15. GLOBAL RADIOPHARMACEUTICAL MANUFACTURING MARKET

15.1. Chapter Overview

15.2. Assumptions and Methodology

15.3. Global Radiopharmaceutical Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

15.3.1. Scenario Analysis

15.3.1.1. Conservative Scenario

15.3.1.2. Optimistic Scenario

15.4. Key Market Segmentations

+ 16. RADIOPHARMACEUTICAL MANUFACTURING MARKET, BY APPLICATION AREA

16.1. Chapter Overview

16.2. Assumptions and Methodology

16.3. Radiopharmaceutical Manufacturing Market: Distribution by Application Area

16.3.1. Radiopharmaceutical Manufacturing Market for Diagnostic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

16.3.2. Radiopharmaceutical Manufacturing Market for Therapeutic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

16.4. Data Triangulation and Validation

+ 17. RADIOPHARMACEUTIAL MANUFACTURING MARKET, BY TYPE OF DIAGNOSTIC RADIOPHARMACEUTICAL

17.1. Chapter Overview

17.2. Assumptions and Methodology

17.3. Radiopharmaceutical Manufacturing Market: Distribution by Type of Diagnostic Radiopharmaceutical

17.3.1. Radiopharmaceutical Manufacturing Market for SPECT Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.3.2. Radiopharmaceutical Manufacturing Market for PET Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17.4. Data Triangulation and Validation

+ 18. RADIOPHARMACEUTICAL MANUFACTURING MARKET, BY TYPE OF THERAPEUTIC RADIOPHARMACEUTICAL

18.1. Chapter Overview

18.2. Assumptions and Methodology

18.3. Radiopharmaceutical Manufacturing Market: Distribution by Type of Therapeutic Radiopharmaceutical

18.3.1. Radiopharmaceutical Manufacturing Market for Gamma Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.3.2. Radiopharmaceutical Manufacturing Market for Beta Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.3.3. Radiopharmaceutical Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18.4. Data Triangulation and Validation

+ 19. RADIOPHARMACEUTICAL MANUFACTURING MARKET, BY TYPE OF RADIOISOTOPE

19.1. Chapter Overview

19.2. Assumptions and Methodology

19.3. Radiopharmaceutical Manufacturing Market: Distribution by Type of Radioisotope

19.3.1. Radiopharmaceutical Manufacturing Market for Technetium-99m: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.3.2. Radiopharmaceutical Manufacturing Market for Lutetium-177: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.3.3. Radiopharmaceutical Manufacturing Market for Fluorine-18: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.3.4. Radiopharmaceutical Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19.4. Data Triangulation and Validation

+ 20. RADIOPHARMACEUTICAL MANUFACTURING MARKET, BY PURPOSE OF MANUFACTURING

20.1. Chapter Overview

20.2. Key Assumptions and Methodology

20.3. Radiopharmaceutical Manufacturing Market: Distribution by Purpose of Manufacturing

20.3.1. Radiopharmaceutical Manufacturing Market for Contract Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

20.3.2. Radiopharmaceutical Manufacturing Market for In-House Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

20.4. Data Triangulation and Validation

+ 21. RADIOPHARMACEUTICAL MANUFACTURING MARKET, BY SOURCE OF MANUFACTURING

21.1. Chapter Overview

21.2. Assumptions and Methodology

21.3. Radiopharmaceutical Manufacturing Market: Distribution by Source of Manufacturing

21.3.1. Radiopharmaceutical Manufacturing Market for Nuclear Reactors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.3.2. Radiopharmaceutical Manufacturing Market for Accelerators / Cyclotrons: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.3.3. Radiopharmaceutical Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21.4. Data Triangulation and Validation

+ 22. RADIOPHARMACEUTICAL MANUFACTURING MARKET, BY SCALE OF OPERATION

22.1. Chapter Overview

22.2. Key Assumptions and Methodology

22.3. Radiopharmaceutical Manufacturing Market: Distribution by Scale of Operation

22.3.1. Radiopharmaceutical Manufacturing Market for Preclinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

22.3.2. Radiopharmaceutical Manufacturing Market for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

22.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

22.4. Data Triangulation and Validation

+ 23. RADIOPHARMACEUTICAL MANUFACTURING MARKET, DISTRIBUTION BY THERAPEUTIC AREA

23.1. Chapter Overview

23.2. Key Assumptions and Methodology

23.3. Radiopharmaceutical Manufacturing Market: Distribution by Therapeutic Area

23.3.1. Radiopharmaceutical Manufacturing Market for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23.3.2. Radiopharmaceutical Manufacturing Market for Cardiovascular Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23.3.3. Radiopharmaceutical Manufacturing Market for Neurological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23.3.4. Radiopharmaceutical Manufacturing Market for Hormonal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23.3.5. Radiopharmaceutical Manufacturing Market for Gastrointestinal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23.3.6. Radiopharmaceutical Manufacturing Market for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23.4. Data Triangulation

+ 24. RADIOPHARMACEUTICAL MANUFACTURING MARKET, DISTRIBUTION BY GEOGRAPHICAL REGIONS

24.1. Chapter Overview

24.2. Key Assumptions and Methodology

24.3. Radiopharmaceutical Manufacturing Market: Distribution by Geographical Regions

24.3.1. Radiopharmaceutical Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.1 Radiopharmaceutical Manufacturing Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.2 Radiopharmaceutical Manufacturing Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.2. Radiopharmaceutical Manufacturing Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.2.1 Radiopharmaceutical Manufacturing Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.2.2 Radiopharmaceutical Manufacturing Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.2.3 Radiopharmaceutical Manufacturing Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.2.4 Radiopharmaceutical Manufacturing Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.2.5 Radiopharmaceutical Manufacturing Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.2.6 Radiopharmaceutical Manufacturing Market in the Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3. Radiopharmaceutical Manufacturing Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.1 Radiopharmaceutical Manufacturing Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.2 Radiopharmaceutical Manufacturing Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.3 Radiopharmaceutical Manufacturing Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.4 Radiopharmaceutical Manufacturing Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.5 Radiopharmaceutical Manufacturing Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.3.6 Radiopharmaceutical Manufacturing Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.4. Radiopharmaceutical Manufacturing Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.4.1 Radiopharmaceutical Manufacturing Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.4.2 Radiopharmaceutical Manufacturing Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.5. Radiopharmaceutical Manufacturing Market in Middle East and Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3. 5.1 Radiopharmaceutical Manufacturing Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.5.2 Radiopharmaceutical Manufacturing Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.3.5.3 Radiopharmaceutical Manufacturing Market in Rest of Middle East and Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24.4. Market Dynamics Assessment

24.4.1. Market Movement Analysis

24.4.2. Penetration-Growth (P-G) Matrix

24.5. Data Triangulation and Validation

+ 25. RADIOPHARMACEUTICAL MANUFACTURING MARKET: NORTH AMERICA

25.1. Radiopharmaceutical Manufacturing Market in North America: Distribution by Application Area

25.1.1. Radiopharmaceutical Manufacturing Market in North America for Diagnostic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.1.2. Radiopharmaceutical Manufacturing Market in North America for Therapeutic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.2. Radiopharmaceutical Manufacturing Market in North America: Distribution by Type of Diagnostic Radiopharmaceutical

25.2.1. Radiopharmaceutical Manufacturing Market in North America for SPECT Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.2.2. Radiopharmaceutical Manufacturing Market in North America for PET Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.3. Radiopharmaceutical Manufacturing Market in North America: Distribution by Type of Therapeutic Radiopharmaceutical

25.3.1. Radiopharmaceutical Manufacturing Market in North America for Gamma Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.3.2. Radiopharmaceutical Manufacturing Market in North America for Beta Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.3.3. Radiopharmaceutical Manufacturing Market in North America for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.3. Radiopharmaceutical Manufacturing Market in North America: Distribution by Type of Radioisotope

25.3.1. Radiopharmaceutical Manufacturing Market in North America for Technetium-99m: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.3.2. Radiopharmaceutical Manufacturing Market in North America for Lutetium-177: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.3.3. Radiopharmaceutical Manufacturing Market in North America for Fluorine-18: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.3.4. Radiopharmaceutical Manufacturing Market in North America for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.4. Radiopharmaceutical Manufacturing Market in North America: Distribution by Purpose of Manufacturing

25.4.1. Radiopharmaceutical Manufacturing Market in North America for Contract Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.4.2. Radiopharmaceutical Manufacturing Market in North America for In-House Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.5. Radiopharmaceutical Manufacturing Market in North America: Distribution by Source of Manufacturing

25.5.1. Radiopharmaceutical Manufacturing Market in North America for Nuclear Reactors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.5.2. Radiopharmaceutical Manufacturing Market in North America for Accelerators / Cyclotrons: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.5.3. Radiopharmaceutical Manufacturing Market in North America for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.6. Radiopharmaceutical Manufacturing Market in North America: Distribution by Scale of Operation

25.6.1. Radiopharmaceutical Manufacturing Market in North America for Preclinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.6.2. Radiopharmaceutical Manufacturing Market in North America for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.6.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in North America for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.7. Radiopharmaceutical Manufacturing Market in North America: Distribution by Therapeutic Area

25.7.1. Radiopharmaceutical Manufacturing Market in North America for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.7.2. Radiopharmaceutical Manufacturing Market in North America for Cardiovascular Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.7.3. Radiopharmaceutical Manufacturing Market in North America for Neurological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.7.4. Radiopharmaceutical Manufacturing Market in North America for Hormonal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.7.5. Radiopharmaceutical Manufacturing Market in North America for Gastrointestinal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25.7.6. Radiopharmaceutical Manufacturing Market in North America for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

+ 26. RADIOPHARMACEUTICAL MANUFACTURING MARKET: EUROPE

26.1. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Application Area

26.1.1. Radiopharmaceutical Manufacturing Market in Europe for Diagnostic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.1.2. Radiopharmaceutical Manufacturing Market in Europe for Therapeutic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.2. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Type of Diagnostic Radiopharmaceutical

26.2.1. Radiopharmaceutical Manufacturing Market in Europe for SPECT Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.2.2. Radiopharmaceutical Manufacturing Market in Europe for PET Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.3. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Type of Therapeutic Radiopharmaceutical

26.3.1. Radiopharmaceutical Manufacturing Market in Europe for Gamma Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.3.2. Radiopharmaceutical Manufacturing Market in Europe for Beta Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.3.3. Radiopharmaceutical Manufacturing Market in Europe for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.3. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Type of Radioisotope

26.3.1. Radiopharmaceutical Manufacturing Market in Europe for Technetium-99m: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.3.2. Radiopharmaceutical Manufacturing Market in Europe for Lutetium-177: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.3.3. Radiopharmaceutical Manufacturing Market in Europe for Fluorine-18: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.3.4. Radiopharmaceutical Manufacturing Market in Europe for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.4. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Purpose of Manufacturing

26.4.1. Radiopharmaceutical Manufacturing Market in Europe for Contract Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.4.2. Radiopharmaceutical Manufacturing Market in Europe for In-House Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.5. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Source of Manufacturing

26.5.1. Radiopharmaceutical Manufacturing Market in Europe for Nuclear Reactors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.5.2. Radiopharmaceutical Manufacturing Market in Europe for Accelerators / Cyclotrons: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.5.3. Radiopharmaceutical Manufacturing Market in Europe for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.6. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Scale of Operation

26.6.1. Radiopharmaceutical Manufacturing Market in Europe for Preclinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.6.2. Radiopharmaceutical Manufacturing Market in Europe for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.6.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Europe for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.7. Radiopharmaceutical Manufacturing Market in Europe: Distribution by Therapeutic Area

26.7.1. Radiopharmaceutical Manufacturing Market in Europe for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.7.2. Radiopharmaceutical Manufacturing Market in Europe for Cardiovascular Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.7.3. Radiopharmaceutical Manufacturing Market in Europe for Neurological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.7.4. Radiopharmaceutical Manufacturing Market in Europe for Hormonal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.7.5. Radiopharmaceutical Manufacturing Market in Europe for Gastrointestinal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26.7.6. Radiopharmaceutical Manufacturing Market in Europe for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

+ 27. RADIOPHARMACEUTICAL MANUFACTURING MARKET: ASIA-PACIFIC

27.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Application Area

27.1.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Diagnostic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.1.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Therapeutic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Type of Diagnostic Radiopharmaceutical

27.2.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for SPECT Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.2.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for PET Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.3. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Type of Therapeutic Radiopharmaceutical

27.3.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Gamma Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.3.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Beta Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.3.3. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.3. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Type of Radioisotope

27.3.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Technetium-99m: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.3.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Lutetium-177: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.3.3. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Fluorine-18: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.3.4. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.4. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Purpose of Manufacturing

27.4.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Contract Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.4.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for In-House Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.5. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Source of Manufacturing

27.5.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Nuclear Reactors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.5.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Accelerators / Cyclotrons: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.5.3. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.6. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation

27.6.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Preclinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.6.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.6.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Asia-Pacific for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.7. Radiopharmaceutical Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area

27.7.1. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.7.2. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Cardiovascular Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.7.3. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Neurological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.7.4. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Hormonal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.7.5. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Gastrointestinal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27.7.6. Radiopharmaceutical Manufacturing Market in Asia-Pacific for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

+ 28. RADIOPHARMACEUTICAL MANUFACTURING MARKET: LATIN AMERICA

28.1. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Application Area

28.1.1. Radiopharmaceutical Manufacturing Market in Latin America for Diagnostic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.1.2. Radiopharmaceutical Manufacturing Market in Latin America for Therapeutic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.2. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Type of Diagnostic Radiopharmaceutical

28.2.1. Radiopharmaceutical Manufacturing Market in Latin America for SPECT Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.2.2. Radiopharmaceutical Manufacturing Market in Latin America for PET Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.3. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Type of Therapeutic Radiopharmaceutical

28.3.1. Radiopharmaceutical Manufacturing Market in Latin America for Gamma Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.3.2. Radiopharmaceutical Manufacturing Market in Latin America for Beta Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.3.3. Radiopharmaceutical Manufacturing Market in Latin America for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.3. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Type of Radioisotope

28.3.1. Radiopharmaceutical Manufacturing Market in Latin America for Technetium-99m: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.3.2. Radiopharmaceutical Manufacturing Market in Latin America for Lutetium-177: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.3.3. Radiopharmaceutical Manufacturing Market in Latin America for Fluorine-18: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.3.4. Radiopharmaceutical Manufacturing Market in Latin America for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.4. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Purpose of Manufacturing

28.4.1. Radiopharmaceutical Manufacturing Market in Latin America for Contract Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.4.2. Radiopharmaceutical Manufacturing Market in Latin America for In-House Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.5. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Source of Manufacturing

28.5.1. Radiopharmaceutical Manufacturing Market in Latin America for Nuclear Reactors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.5.2. Radiopharmaceutical Manufacturing Market in Latin America for Accelerators / Cyclotrons: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.5.3. Radiopharmaceutical Manufacturing Market in Latin America for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.6. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Scale of Operation

28.6.1. Radiopharmaceutical Manufacturing Market in Latin America for Preclinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.6.2. Radiopharmaceutical Manufacturing Market in Latin America for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.6.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Latin America for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.7. Radiopharmaceutical Manufacturing Market in Latin America: Distribution by Therapeutic Area

28.7.1. Radiopharmaceutical Manufacturing Market in Latin America for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.7.2. Radiopharmaceutical Manufacturing Market in Latin America for Cardiovascular Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.7.3. Radiopharmaceutical Manufacturing Market in Latin America for Neurological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.7.4. Radiopharmaceutical Manufacturing Market in Latin America for Hormonal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.7.5. Radiopharmaceutical Manufacturing Market in Latin America for Gastrointestinal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

28.7.6. Radiopharmaceutical Manufacturing Market in Latin America for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

+ 29. RADIOPHARMACEUTICAL MANUFACTURING MARKET: MIDDLE EAST AND NORTH AFRICA

29.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Application Area

29.1.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Diagnostic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.1.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Therapeutic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Type of Diagnostic Radiopharmaceutical

29.2.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for SPECT Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.2.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for PET Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.3. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Type of Therapeutic Radiopharmaceutical

29.3.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Gamma Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.3.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Beta Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.3.3. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.3. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Type of Radioisotope

29.3.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Technetium-99m: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.3.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Lutetium-177: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.3.3. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Fluorine-18: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.3.4. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.4. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Purpose of Manufacturing

29.4.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Contract Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.4.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for In-House Manufacturing Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.5. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Source of Manufacturing

29.5.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Nuclear Reactors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.5.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Accelerators / Cyclotrons: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.5.3. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.6. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation

29.6.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Preclinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.6.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.6.3. Nuclear Medicine and Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.7. Radiopharmaceutical Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area

29.7.1. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.7.2. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Cardiovascular Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.7.3. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Neurological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.7.4. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Hormonal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.7.5. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Gastrointestinal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

29.7.6. Radiopharmaceutical Manufacturing Market in Middle East and North Africa for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

**Detailed information on Chapters 25-29 is available in the Excel Data Packs shared along with the report**

+ 30. CONCLUSION

+ 31. EXECUTIVE INSIGHTS

31.1. Chapter Overview

31.2. Company A

31.2.1. Company Snapshot

31.2.2. Interview Transcript: Head of Business Unit Pharmaceuticals

31.3. Company B

31.3.1. Company Snapshot

31.3.2. Interview Transcript: Senior Vice President of Business Development

31.4. Company C

31.4.1. Company Snapshot

31.4.2. Interview Transcript: Former Vice President, Quality / R&D

31.5. Company D

31.5.1. Company Snapshot

31.5.2. Interview Transcript: Professor of Nuclear Medicine

31.6. Company E

31.6.1. Company Snapshot

31.6.2. Interview Transcript: Retired Professor of Medical Imaging / Nuclear Medicine Physician

31.7. Company F

31.7.1. Company Snapshot

31.7.2. Interview Transcript: Professor and Associate Director

31.8. Company G

31.8.1. Company Snapshot

31.8.2. Interview Transcript: Anonymous

+ 32. APPENDIX 1: TABULATED DATA

+ 33. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

+ List of Figures

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Forecast Methodology

Figure 2.3 Research Methodology: Robust Quality Control

Figure 2.4 Research Methodology: Key Market Segmentations

Figure 5.1 Executive Summary: Market Landscape of Radiopharmaceutical Manufacturing Market

Figure 5.2 Executive Summary: Partnerships and Collaborations

Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis

Figure 6.1 Structure of a Radiopharmaceutical

Figure 6.2 Production of Radiopharmaceuticals: Radionuclide Generator

Figure 6.3 Production of Radiopharmaceuticals: Particle Accelerator (Cyclotron)

Figure 6.4 Production of Radiopharmaceuticals: Nuclear Reactor

Figure 6.5 Geographical Distribution of Regulatory Bodies Governing the Production of Radiopharmaceuticals

Figure 6.6 Selecting a CMO Partner for Radiopharmaceuticals Production: Parameters to Consider

Figure 7.1 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Year of Establishment

Figure 7.2 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size

Figure 7.3 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Headquarters

Figure 7.4 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters

Figure 7.5 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company

Figure 7.6 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Manufacturing Facilities

Figure 7.7 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Application Area

Figure 7.8 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured

Figure 7.9 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured

Figure 7.10 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured

Figure 7.11 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured

Figure 7.12 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Beta Emitters Manufactured

Figure 7.13 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Alpha Emitters Manufactured

Figure 7.14 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Service Offered

Figure 7.15 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Scale of Operation

Figure 7.16 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Therapeutic Area

Figure 8.1 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Location of Headquarters

Figure 8.2 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization

Figure 8.3 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Application area

Figure 8.4 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured

Figure 8.5 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured

Figure 8.6 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured

Figure 8.7 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured

Figure 8.8 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Beta Emitters Manufactured

Figure 8.9 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Purpose of Manufacturing

Figure 8.10 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Therapeutic Area

Figure 9.1 Company Competitiveness Analysis: Players based in North America (Peer Group I)

Figure 9.2 Company Competitiveness Analysis: Players based in Europe (Peer Group II)

Figure 9.3 Company Competitiveness Analysis: Players based in Asia-Pacific and Rest of the World (Peer Group III)

Figure 9.4 Company Competitiveness Analysis: Radiopharmaceutical Manufacturers based in North America (Peer Group I)

Figure 9.5 Company Competitiveness Analysis: Players based in Europe (Peer Group II)

Figure 9.6 Company Competitiveness Analysis: Players based in Asia-Pacific and Rest of the World (Peer Group III)

Figure 11.1 Partnerships and Collaborations: Distribution by Quarterly Trend of Partnership, Since Q1 2025

Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership

Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Q1 2025

Figure 11.4 Partnerships and Collaborations: Distribution by Application Area

Figure 11.5 Partnerships and Collaborations: Distribution by Type of Radioisotope Involved

Figure 11.6 Partnerships and Collaborations: Distribution by Type of Partner

Figure 11.7 Most Active Players: Distribution by Number of Partnerships

Figure 11.8 Partnerships and Collaborations: Distribution by Local and International Agreements

Figure 11.9 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Deals

Figure 12.1 Supply Chain of Mo-99 (Tc-99m)

Figure 12.2 Geographical Location of Major Nuclear Reactors

Figure 13.1 Strategic Roadmap: Short, Mid and Long-Term Initiatives

Figure 13.2 Regional Gap Assessment of Manufacturing Facilities in America (in terms of Application Areas)

Figure 13.3 Regional Gap Assessment of Manufacturing Facilities in Europe (in terms of Application Areas)

Figure 13.4 Regional Gap Assessment of Manufacturing Facilities in Aisa-Pacific and Middle East (in terms of Application Areas)

Figure 14.1 Market Impact Analysis: Drivers

Figure 14.2 Market Impact Analysis: Restraints

Figure 14.3 Market Impact Analysis: Opportunities

Figure 14.4 Market Impact Analysis: Challenges

Figure 15.1 Global Radiopharmaceutical Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Base Scenario (USD Billion)

Figure 15.2 Global Radiopharmaceutical Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)

Figure 15.3 Global Radiopharmaceutical Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)

Figure 16.1 Radiopharmaceutical Manufacturing Market: Distribution by Application Area,

Figure 16.2 Radiopharmaceutical Manufacturing Market for Diagnostic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 16.3 Radiopharmaceutical Manufacturing Market for Therapeutic Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 17.1 Radiopharmaceutical Manufacturing Market: Distribution by Type of Diagnostic Radiopharmaceutical, 2023,2026 and 2035

Figure 17.2 Radiopharmaceutical Manufacturing Market for SPECT Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 17.3 Radiopharmaceutical Manufacturing Market for PET Radiopharmaceuticals: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 18.1 Radiopharmaceutical Manufacturing Market: Distribution by Type of Therapeutic Radiopharmaceutical,

Figure 18.2 Radiopharmaceutical Manufacturing Market for Gamma Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 18.3 Radiopharmaceutical Manufacturing Market for Beta Emitters: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 18.4 Radiopharmaceutical Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 19.1 Radiopharmaceutical Manufacturing Market: Distribution by Type of Radioisotope,

Figure 19.2 Radiopharmaceutical Manufacturing Market for Technetium-99m Radioisotopes: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 19.3 Radiopharmaceutical Manufacturing Market for Lutetium-177 Radioisotopes: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 19.4 Radiopharmaceutical Manufacturing Market for Fluorine-18 Radioisotopes: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 19.5 Radiopharmaceutical Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 20.1 Radiopharmaceutical Manufacturing Market: Distribution by Purpose of Manufacturing,

Figure 20.2 Radiopharmaceutical Manufacturing Market for Contract Manufacturing: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 20.3 Radiopharmaceutical Manufacturing Market for In-House Manufacturing: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 21.1 Radiopharmaceutical Manufacturing Market: Distribution by Source of Manufacturing,

Figure 21.2 Radiopharmaceutical Manufacturing Market for Nuclear Reactors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 21.3 Radiopharmaceutical Manufacturing Market for Accelerators / Cyclotrons: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 21.4 Radiopharmaceutical Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 22.1 Radiopharmaceutical Manufacturing Market: Distribution by Scale of Operation

Figure 22.2 Radiopharmaceutical Manufacturing Market for Preclinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 22.3 Radiopharmaceutical Manufacturing Market for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 22.4 Radiopharmaceutical Manufacturing Market for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 23.1 Radiopharmaceutical Manufacturing Market: Distribution by Therapeutic Area, (USD Billion)

Figure 23.2 Radiopharmaceutical Manufacturing Market for Oncological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 23.3 Radiopharmaceutical Manufacturing Market for Cardiovascular Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 23.4 Radiopharmaceutical Manufacturing Market for Neurological Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 23.5 Radiopharmaceutical Manufacturing Market for Hormonal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 23.6 Radiopharmaceutical Manufacturing Market for Gastrointestinal Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 23.7 Radiopharmaceutical Manufacturing Market for Other Disorders: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 24.1 Radiopharmaceutical Manufacturing Market: Distribution by Geographical Regions

Figure 24.2 Radiopharmaceutical Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 24.3 Radiopharmaceutical Manufacturing Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 24.4 Radiopharmaceutical Manufacturing Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 24.5 Radiopharmaceutical Manufacturing Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Figure 24.6 Radiopharmaceutical Manufacturing Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.7 Radiopharmaceutical Manufacturing Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.8 Radiopharmaceutical Manufacturing Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.9 Radiopharmaceutical Manufacturing Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.10 Radiopharmaceutical Manufacturing Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.11 Radiopharmaceutical Manufacturing Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.12 Radiopharmaceutical Manufacturing Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.13 Radiopharmaceutical Manufacturing Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.14 Radiopharmaceutical Manufacturing Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.15 Radiopharmaceutical Manufacturing Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.16 Radiopharmaceutical Manufacturing Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.17 Radiopharmaceutical Manufacturing Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.18 Radiopharmaceutical Manufacturing Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.19 Radiopharmaceutical Manufacturing Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.20 Radiopharmaceutical Manufacturing Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.21 Radiopharmaceutical Manufacturing Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.22 Radiopharmaceutical Manufacturing Market in Middle East and Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.23 Radiopharmaceutical Manufacturing Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.24 Radiopharmaceutical Manufacturing Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 24.25 Radiopharmaceutical Manufacturing Market in Rest of Middle East and Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Figure 25.1 Conclusion: Radiopharmaceutical Manufacturers (Industry Players) Market Landscape

Figure 25.2 Conclusion: Radiopharmaceutical Manufacturers (Non-Industry Players) Market Landscape

Figure 25.3 Conclusion: Partnerships and Collaborations

Figure 25.4 Conclusion: Market Forecast and Opportunity Analysis (I / III)

Figure 25.5 Conclusion: Market Forecast and Opportunity Analysis (II / III)

Figure 25.6 Conclusion: Market Forecast and Opportunity Analysis (III / III)

+ List of Tables

Table 27.1 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Year of Establishment

Table 27.2 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size

Table 27.3 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Headquarters

Table 27.4 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Company Size and Location of Headquarters

Table 27.5 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Company

Table 27.6 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Location of Manufacturing Facilities

Table 27.7 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Application area

Table 27.8 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured

Table 27.9 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured

Table 27.10 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured

Table 27.11 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured

Table 27.12 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Alpha Emitters Manufactured

Table 27.13 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Beta Emitters Manufactured

Table 27.14 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Type of Service Offered

Table 27.15 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Scale of Operation

Table 27.16 Radiopharmaceutical Manufacturers (Industry Players): Distribution by Therapeutic Area

Table 27.17 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Location of Headquarters

Table 27.18 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Organization

Table 27.19 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Application area

Table 27.20 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radiopharmaceuticals Manufactured

Table 27.21 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of PET Radiopharmaceuticals Manufactured

Table 27.22 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of SPECT Radiopharmaceuticals Manufactured

Table 27.23 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radiopharmaceuticals Manufactured

Table 27.24 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Type of Beta Emitters Manufactured

Table 27.25 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Purpose of Manufacturing

Table 27.26 Radiopharmaceutical Manufacturers (Non-Industry Players): Distribution by Therapeutic Area

Table 27.27 Partnerships and Collaborations: Distribution by Quarterly Trend of Partnership

Table 27.28 Partnerships and Collaborations: Distribution by Type of Partnership

Table 27.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership

Table 27.30 Partnerships and Collaborations: Distribution by Application area

Table 27.31 Partnerships and Collaborations: Distribution by Type of Radioisotope Involved

Table 27.32 Partnerships and Collaborations: Distribution by Type of Partner

Table 27.33 Most Active Players: Distribution by Number of Partnerships

Table 27.34 Partnerships and Collaborations: Distribution by Local and International Agreements

Table 27.35 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreement

Table 27.36 Radiopharmaceutical Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (2025-2035): Base Scenario (USD Billion)

Table 27.37 Radiopharmaceutical Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)

Table 27.38 Radiopharmaceutical Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)

Table 27.39 Radiopharmaceutical Manufacturing Market: Distribution by Application Area

Table 27.40 Radiopharmaceutical Manufacturing Market for Diagnostic Radiopharmaceuticals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.41 Radiopharmaceutical Manufacturing Market for Therapeutic Radiopharmaceuticals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.42 Radiopharmaceutical Manufacturing Market: Distribution by Type of Diagnostic Radiopharmaceutical, 2023,2026 and 2035

Table 27.43 Radiopharmaceutical Manufacturing Market for SPECT Radiopharmaceuticals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.44 Radiopharmaceutical Manufacturing Market for PET Radiopharmaceuticals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.45 Radiopharmaceutical Manufacturing Market: Distribution by Type of Therapeutic Radiopharmaceutical, 2023,2026 and 2035

Table 27.46 Radiopharmaceutical Manufacturing Market for Gamma Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.47 Radiopharmaceutical Manufacturing Market for Beta Emitters, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.48 Radiopharmaceutical Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.49 Radiopharmaceutical Manufacturing Market: Distribution by Type of Radioisotope

Table 27.50 Radiopharmaceutical Manufacturing Market for Technetium-99m Radioisotopes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.51 Radiopharmaceutical Manufacturing Market for Lutetium-177 Radioisotopes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.52 Radiopharmaceutical Manufacturing Market for Fluorine-18 Radioisotopes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.53 Radiopharmaceutical Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.54 Radiopharmaceutical Manufacturing Market: Distribution by Purpose of Manufacturing, 2023,2026 and 2035

Table 27.55 Radiopharmaceutical Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.56 Radiopharmaceutical Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.57 Radiopharmaceutical Manufacturing Market: Distribution by Source of Manufacturing

Table 27.58 Radiopharmaceutical Manufacturing Market for Nuclear Reactors Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.59 Radiopharmaceutical Manufacturing Market for Accelerators / Cyclotrons, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.60 Radiopharmaceutical Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.61 Radiopharmaceutical Manufacturing Market: Distribution by Scale of Operation

Table 27.62 Radiopharmaceutical Manufacturing Market for Preclinical Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.63 Radiopharmaceutical Manufacturing Market for Clinical Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.64 Radiopharmaceutical Manufacturing Market for Commercial Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.65 Radiopharmaceutical Manufacturing Market: Distribution by Therapeutic Area

Table 27.66 Radiopharmaceutical Manufacturing Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.67 Radiopharmaceutical Manufacturing Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.68 Radiopharmaceutical Manufacturing Market for Neurological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.69 Radiopharmaceutical Manufacturing Market for Hormonal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.70 Radiopharmaceutical Manufacturing Market for Gastrointestinal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.71 Radiopharmaceutical Manufacturing Market for Other Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.72 Radiopharmaceutical Manufacturing Market: Distribution by Key Geographical Regions

Table 27.73 Radiopharmaceutical Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.74 Radiopharmaceutical Manufacturing Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)

Table 27.75 Radiopharmaceutical Manufacturing Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.76 Radiopharmaceutical Manufacturing Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.77 Radiopharmaceutical Manufacturing Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.78 Radiopharmaceutical Manufacturing Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.79 Radiopharmaceutical Manufacturing Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.80 Radiopharmaceutical Manufacturing Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.81 Radiopharmaceutical Manufacturing Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.82 Radiopharmaceutical Manufacturing Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.83 Radiopharmaceutical Manufacturing Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.84 Radiopharmaceutical Manufacturing Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.85 Radiopharmaceutical Manufacturing Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.86 Radiopharmaceutical Manufacturing Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.87 Radiopharmaceutical Manufacturing Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.88 Radiopharmaceutical Manufacturing Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.89 Radiopharmaceutical Manufacturing Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.90 Radiopharmaceutical Manufacturing Market in Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.91 Radiopharmaceutical Manufacturing Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.92 Radiopharmaceutical Manufacturing Market in Rest of Latin America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.93 Radiopharmaceutical Manufacturing Market in Middle East and Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.94 Radiopharmaceutical Manufacturing Market in Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.95 Radiopharmaceutical Manufacturing Market in South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

Table 27.96 Radiopharmaceutical Manufacturing Market in Rest of Middle East and Africa, Historical Trends (Since 2023) and Forecasted Estimates

Radiopharmaceutical Manufacturing Market